- Home
- ISPR vs PYXS Comparison
ISPR vs PYXS Comparison
Compare ISPR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | PYXS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 82.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ISPR | PYXS |
|---|---|---|
| Price | $1.40 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.50 | $7.00 |
| AVG Volume (30 Days) | 60.4K | ★ 369.8K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,494,304.00 | $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.31 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $0.97 |
| 52 Week High | $3.87 | $5.55 |
Technical Indicators
Market Signals| Indicator | ISPR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 54.63 |
| Support Level | N/A | $1.28 |
| Resistance Level | $2.01 | $1.74 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 27.85 | 54.95 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.